6533b7dafe1ef96bd126d8fd

RESEARCH PRODUCT

Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis

Eduard A. ShuralevMahavir SinghFilippo BartalesiChiara Della BellaMario Milco D'eliosAlessia GrassiMichele SpinicciSimona TapinassiAlessandro BartoloniMarisa BenagianoKatja TruthmannArianna TroiloHeba F. Mustafa AlnwaisriSofia D’elios

subject

Bacterial DiseasesMale0301 basic medicinelcsh:MedicineAdult; Aged; Case-Control Studies; Diagnosis Differential; Female; Humans; Immunoassay; Interleukin-2; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; ROC Curve; Species SpecificityFluorescence MicroscopyBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)ZoonosesDiagnosisMedicine and Health SciencesBovine TuberculosisEnzyme-Linked Immunoassayslcsh:ScienceImmunoassayMicroscopyMultidisciplinarybiologyLatent tuberculosismedicine.diagnostic_testELISPOTLight MicroscopyMiddle AgedActinobacteriaInfectious DiseasesTuberculosis Diagnosis and ManagementFemaleResearch ArticleAdultTuberculosis030106 microbiologyResearch and Analysis MethodsQuantiFERONDiagnosis DifferentialMycobacterium tuberculosis03 medical and health sciencesSpecies SpecificityAntigenDiagnostic MedicineLatent TuberculosismedicineTuberculosisHumansImmunoassaysAgedBacteriabusiness.industrylcsh:ROrganismsCase-control studyBiology and Life SciencesMycobacterium tuberculosisTropical Diseasesmedicine.diseasebiology.organism_classificationMycobacterium Ulcerans030104 developmental biologyROC CurveCase-Control StudiesImmunoassayDifferentialImmunologyImmunologic TechniquesInterleukin-2lcsh:Qbusiness

description

Background Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish between latent infection and active tuberculosis is one of the major limits of currently available diagnostic tools. Methods A total of 215 patients were included in the study as active TB cases (n = 73), LTBI subjects (n = 88) and healthy persons (n = 54). Peripheral blood mononuclear cells (PBMCs) were isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot assay was performed to test their proliferative response to M. tuberculosis antigens ESAT-6, CFP-10 and Ala-DH. Statistical analysis was performed to define the sensitivity and the specificity of the LIOSpot® TB kit for each antigen used and to set the best cut off value that enables discrimination between subjects with active TB or latent TB infection. Results Comparing the LIOSpot® TB results for each tested antigen between uninfected and infected subjects and between people with latent infection and active TB disease, the differences were significant for each antigen (p< 0.0001) but the ROC analysis demonstrated a high accuracy for the Ala-DH test only, with a cut off value of 12.5 SFC per million PBMCs and the Ala-DH ROC curve conferred a 96% sensitivity and 100% specificity to the test. For the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a sensitivity of 86% and specificity of 36% was obtained. Finally, the best cut off value for CFP-10 was 231.25 SFC per million PBMCs, with a sensitivity of 80% and a specificity of 54%. Thus, as for IGRA assays such as Quantiferon and T-Spot TB tests, ESAT-6 and CFP-10 are unable to distinguish LTBI from active TB when IL-2 is measured. On the contrary, the IL-2 production induced by Ala-DH, measured by LIOSpot® TB kit, shows high sensitivity and specificity for active TB disease. Conclusions This study demonstrates that the LIOSpot® TB test is a highly useful diagnostic tool to discriminate between latent TB infection and active tuberculosis in adults patients.

https://doi.org/10.1371/journal.pone.0197825